Pentoxifylline (Trental) as a Modulator of Tumor Necrosis Factor and of HIV Replication in Patients With AIDS
Status:
Completed
Trial end date:
1993-03-01
Target enrollment:
Participant gender:
Summary
To determine whether pentoxifylline lowers tumor necrosis factor (TNF) levels in AIDS
patients. Pentoxifylline decreases tumor necrosis factor (TNF), and therefore should decrease
such TNF-intensified events as cachexia, enhanced HIV expression, and inhibition of
zidovudine (AZT) activity.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)